Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells.

doi:10.1038/s41408-020-00352-9

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells.

Blood cancer journal - 25 Aug 2020

Travaglini Serena, Angelini Daniela Francesca, Alfonso Valentina, Guerrera Gisella, Lavorgna Serena, Divona Mariadomenica, Nardozza Anna Maria, Consalvo Maria Irno, Fabiani Emiliano, De Bardi Marco, Neri Benedetta, Forghieri Fabio, Marchesi Francesco, Paterno Giovangiacinto, Cerretti Raffaella, Barragan Eva, Fiori Valentina, Dominici Sabrina, Del Principe Maria Ilaria, Venditti Adriano, Battistini Luca, Arcese William, Lo-Coco Francesco, Voso Maria Teresa, Ottone Tiziana

Abstract excerpt

Acute myeloid leukemia (AML) with FLT3-ITD mutations (FLT3-ITDmut) remains a therapeutic challenge, with a still high relapse rate, despite targeted treatment with tyrosine kinase inhibitors. In this disease, the CD34/CD123/CD25/CD99+ leukemic precursor cells (LPCs) phenotype predicts for FLT3-ITD-positivity. The aim of this study was to characterize the distribution of FLT3-ITD mutation in different progenitor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Prognosis

Share to Protein Kinase Inhibitors

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 32843624
DOI: 10.1038/s41408-020-00352-9
PMCID: PMC7447750

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells.PMID 32843624Read ↗

A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.Semantic proximity Read ↗

Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.Semantic proximity Read ↗

CD123 Is Consistently Expressed on NPM1-Mutated AML CellsSemantic proximity Read ↗

CD99 is a therapeutic target on disease stem cells in myeloid malignancies.Semantic proximity Read ↗

Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implicationsSemantic proximity Read ↗

FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.Semantic proximity Read ↗

Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemiaSemantic proximity Read ↗

CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotypingSemantic proximity Read ↗

CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.Semantic proximity Read ↗

Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor.Semantic proximity Read ↗

Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the FLT3-ITD/NPM1-MUT myeloblastic/monocytic bulk AML blastic populations.Semantic proximity Read ↗

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.